ADIAL PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Adial Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2017 to Q2 2024.
  • Adial Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$2.46M, a 326% decline year-over-year.
  • Adial Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$12.2M, a 57% decline year-over-year.
  • Adial Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$5.12M, a 59.8% increase from 2022.
  • Adial Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$12.7M, a 34.5% increase from 2021.
  • Adial Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$19.4M, a 78.3% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$12.2M -$2.46M -$3.55M -326% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$8.69M -$6.48M -$3.57M -123% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-13
Q4 2023 -$5.12M -$1.92M +$946K +33% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$6.07M -$1.38M +$1.72M +55.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$7.79M $1.09M +$4.94M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$12.7M -$2.91M +$2K +0.07% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-13
Q4 2022 -$12.7M -$2.87M +$2.96M +50.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$15.7M -$3.11M +$1.21M +28% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$16.9M -$3.85M +$593K +13.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$17.5M -$2.91M +$1.93M +39.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$19.4M -$5.83M -$2.36M -68.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$17.1M -$4.32M -$982K -29.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$16.1M -$4.44M -$2.63M -145% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$13.4M -$4.83M -$2.56M -112% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$10.9M -$3.47M -$1.41M -68.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 -$9.48M -$3.34M -$1.62M -94.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$7.86M -$1.81M +$323K +15.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$8.19M -$2.28M +$406K +15.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$8.59M -$2.06M -$789K -62.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-22
Q3 2019 -$7.8M -$1.72M +$6.48M +79.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$14.3M -$2.13M -$342K -19.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$13.9M -$2.68M -$2.3M -608% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$11.6M -$1.27M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-20
Q3 2018 -$8.19M -$7.9M -2699% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$1.79M -$1.53M -578% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$379K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q3 2017 -$293K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$264K Apr 1, 2017 Jun 30, 2017 10-Q 2018-09-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.